News › Clinical Practice, Industry News, Patient Care

Galderma Announces Results from Phase 2 Clinical Dose-escalating Study with Azzalure / Dysport

November 18, 2020

Galderma has announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of moderate to severe frown lines between the eyebrows (glabellar lines). Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport at all four doses achieving a composite two-grade improvement responder rate than those treated with placebo at one month. Data from secondary endpoints demonstrated promising results for a potential prolonged duration of effect correlated with higher doses. Dysport, also marketed as Azzalure in some countries, is a prescription injection.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Peptides 101: What Every Practice Needs to Know Before the Boom Arrives
    • HHS Announces Interim Enforcement Discretion for Six Peptides
    • Positioned Advisory Services Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • CareCredit Introduces CareCredit Pay Later
    • Galderma Launches Alastin Restorative Eye Complex with TriHex+
Advertisement